Case Study: Top Pharma Company achieves better oncology market targeting with Axtria

Strategic Course Correction For A Blockbuster Oncology Drug

Top Pharma Company, a leading pharmaceutical firm, had successfully grown its oncology drug into blockbuster status but was struggling to understand its full market potential and optimize sales targeting. Axtria helped the company by applying advanced analytics to patient-level claims data, enabling a more accurate view of penetration and opportunity across tumor types, lines of therapy, regimens, and accounts.

Axtria combined longitudinal patient history with account-level unit data to estimate market potential and product penetration more reliably, despite gaps in the underlying claims data. As a result, the client gained a clearer understanding of opportunity by tumor type and regimen, reps were equipped with more actionable targeting insights, and resources could be allocated more effectively to high-potential areas.